Unknown PHASE2 INTERVENTIONAL 2-arm NCT01216982

Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders

Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial

Sponsor: GlaxoSmithKline

Conditions Combat Disorders Depression Mood Disorders Stress Disorders

Interventions Lovaza, omega-3 fatty acid ethyl ester Placebo, visually identical to Lovaza

Updated 6 times since 2017 Last updated: Mar 8, 2011 Started: Nov 30, 2010 Primary completion: Feb 28, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01216982, this PHASE2 trial focuses on Combat Disorders and Depression and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2010, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
United States Department of Defense

Data source: United States Department of Defense

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Camp Taji, Iraq